Evidence map›Paper›PMID 32582140›Full record

ArticleFrontiers in immunology2020

Fauzia Jamal, Manish K Singh, Jagadish Hansa, Pushpanjali, Ghufran Ahmad, Manas Ranjan Dikhit, Mohd Saad Umar, Sanjiva Bimal, Pradeep Das, Anzar Abdul Mujeeb and 3 more

RetractedErratum issuedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Correction · 2020-09-09Error in Image · Updated to Retraction · · Correction also retracted by article retraction.
  • Retraction · 2021-06-14Duplication of/in Image · Investigation by Journal/Publisher · Objections by Author(s) · Original Data and/or Images not Provided and/or not Available · Unreliable Data · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) · · Corrigendum retracted separately with PMID 34249025 and DOI 10.3389/fimmu.2021.724893;
  • Erratum issued
  • Retracted
5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Fauzia JamalInterdesciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Manish K SinghDepartment of Microbiology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Jagadish HansaDepartment of Microbiology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
PushpanjaliDepartment of Microbiology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Ghufran AhmadDepartment of Microbiology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Manas Ranjan DikhitDepartment of Bioinformatics, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Mohd Saad UmarInterdesciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Sanjiva BimalDepartment of Immunology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Pradeep DasDepartment of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Anzar Abdul MujeebInterdesciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Shubhankar K SinghDepartment of Microbiology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Swaleha ZubairDepartment of Computer Science, Aligarh Muslim University, Aligarh, India.
Mohammad OwaisInterdesciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Rajendra Memorial Research Institute of Medical Sciences · INAligarh Muslim University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visceral leishmaniasis (VL)-related mortality and morbidity imposes a great deal of health concern across the globe. The existing anti-leishmanial drug regimen generally fails to eliminate newly emerging resistant isolates of this dreadful parasite. In such circumstances, the development of a prophylactic strategy to impart protection against the disease is likely to take center stage. In order to develop a promising prophylactic vaccine, it is desirable to identify an adequately potential vaccine candidate.

Indexed as

AdolescentAdultAnimalsCell PolarityDisease Models, AnimalFemaleHost-Pathogen InteractionsHumansLeishmania donovaniLeishmaniasis VaccinesLeishmaniasis, VisceralMaleMAP Kinase Signaling SystemMiceMice, Inbred BALB CMicrotubule-Associated ProteinsLeishmaniasis VaccinesMicrotubule-Associated Proteinsp38 Mitogen-Activated Protein KinasesProtozoan Proteinshumoral responseimmunoprophylaxisLeishmania donovaniMAPK signalingpeptide cocktailT-cell proliferationTh1 responsetubulin folding cofactor D

Identifiers

PMID32582140
PMCPMC7280453
OpenAlexW3033053783

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.